Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 4/20 | 0.64 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.50 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | ACACB | O00763 | 1/20 | 0.38 |
| ▸ | ACACA | Q13085 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.38 |
| ▸ | MMP12 | P39900 | 2/20 | 0.37 |
| ▸ | MMP13 | P45452 | 2/20 | 0.37 |
| ▸ | MMP2 | P08253 | 1/20 | 0.37 |
| ▸ | MMP9 | P14780 | 1/20 | 0.37 |
| ▸ | MMP14 | P50281 | 1/20 | 0.37 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL667385 | 1.00 | GPR84 (0.64) | GPR84SLC22A6GABRR1LMNAFFAR4 | |
| SCHEMBL667943 | 1.00 | GPR84 (0.64) | GPR84SLC22A6GABRR1LMNAFFAR4 | |
| SCHEMBL4748559 | 1.00 | GPR84 (0.64) | GPR84SLC22A6GABRR1LMNAFFAR4 | |
| SCHEMBL6232898 | 1.00 | GPR84 (0.64) | GPR84SLC22A6GABRR1LMNAFFAR4 | |
| SCHEMBL5158401 | 1.00 | GPR84 (0.64) | GPR84SLC22A6GABRR1LMNAFFAR4 | |
| SCHEMBL5158740 | 0.98 | GPR84 (0.61) | GPR84SLC22A6GABRR1LMNAFFAR4 | |
| SCHEMBL666360 | 0.91 | GPR84 (0.57) | GPR84SLC22A6GABRR1LMNAFFAR4 | |
| SCHEMBL4745085 | 0.91 | GPR84 (0.57) | GPR84SLC22A6GABRR1LMNAFFAR4 | |
| SCHEMBL27394390 | 0.91 | GPR84 (0.57) | GPR84SLC22A6GABRR1LMNAFFAR4 | |
| SCHEMBL966415 | 0.86 | GPR84 (0.74) | GPR84SLC22A6GABRR1LMNAFFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160207938-A1 | QUINAZOLINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2016-07-21 | — | — | US | disclosed |
| US-9273013-B2 | Quinazoline derivatives | JANSSEN PHARMACEUTICA NV (BE) | 2016-03-01 | — | — | US | disclosed |
| US-20130178624-A1 | QUINAZOLINE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2013-07-11 | — | — | US | disclosed |
| US-8394786-B2 | Quinazoline derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 2013-03-12 | — | — | US | disclosed |
| EP-1633365-B1 | MACROCYCLIC QUINAZOLINE DERIVATIVES AS ANTIPROLIFERATIVE AGENTS | JANSSEN PHARMACEUTICA NV (BE) | 2012-02-08 | — | — | EP | disclosed |
| EP-2305687-A1 | Quinazoline derivatives | Janssen Pharmaceutica NV (BE) | 2011-04-06 | — | — | EP | disclosed |
| US-20100105668-A1 | Quinazoline derivatives | FREYNE EDDY JEAN EDGARD | 2010-04-29 | — | — | US | disclosed |
| US-7648975-B2 | Macrocyclic quinazoline derivatives as antiproliferative agents | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-01-19 | — | — | US | disclosed |
| US-20060247237-A1 | Macrocyclic quinazoline derivatives as antiproliferative agents | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-11-02 | — | — | US | disclosed |
| EP-1633365-A1 | MACROCYCLIC QUINAZOLINE DERIVATIVES AS ANTIPROLIFERATIVE AGENTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-03-15 | — | — | EP | disclosed |
| WO-2004105765-A1 | MACROCYCLIC QUINAZOLINE DERIVATIVES AS ANTIPROLIFERATIVE AGENTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-12-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130178624-A1 | QUINAZOLINE DERIVATIVES | NR1H2, NR1H3, NR3C2 | GPR84 261/4885SLC22A6 566/4885GABRR1 681/4885 |
| US-20060247237-A1 | Macrocyclic quinazoline derivatives as antiproliferative agents | NR1H3, NR1H2, NCOA3 | GPR84 1132/4885SLC22A6 1613/4885GABRR1 1807/4885 |
| US-20100105668-A1 | Quinazoline derivatives | NR1H2, NR1H3, NR3C2 | GPR84 255/4885SLC22A6 488/4885GABRR1 613/4885 |
| US-20160207938-A1 | QUINAZOLINE DERIVATIVES | NR1H2, NR1H3, NR3C2 | GPR84 534/4885SLC22A6 454/4885GABRR1 599/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.